Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTA, Biodentine, and Vitrebond for deep decay in primary teeth
NCT02298504Phase 4Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Jul 2018
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of mineral trioxide aggregate and Biodentine in dental caries and reversible pulpitis (3 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Clinical success after pulpotomy at 3 years, Clinical success after indirect pulp cap at 3 years and 1 more. Started Jul 2018; status: completed.
02
Drugs
mineral trioxide aggregateBiodentine
03
Conditions
dental cariesreversible pulpitis
Beyond the preview
Go deeper on NCT02298504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02298504.